EP
RNAC icon

Essential Partners’s Cartesian Therapeutics RNAC Stock Holding History

Essential Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.5K Sell
432
-165
-28% -$1.22K ﹤0.01% 1596
2026
Q1 		$3.67K Buy
+597
New +$4.25K ﹤0.01% 1725
2025
Q4 		– Sell
-14
Closed -$143 – 2895
2025
Q3 		$143 Sell
14
-1
-7% -$11 ﹤0.01% 2449
2025
Q2 		$156 Buy
+15
New +$160 ﹤0.01% 1999

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essential Partners's RNAC Position: Q2 2026 in Review

Essential Partners reduced its Cartesian Therapeutics (RNAC) stake by 28% in Q2 2026, selling an estimated $1.22K and leaving 432 shares worth $4.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1596.

Essential Partners first reported a position in RNAC in Q2 2025 and has held it in 4 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Essential Partners held 432 shares of Cartesian Therapeutics worth $4.5K as of Q2 2026.
  • Essential Partners sold 165 Cartesian Therapeutics shares in Q2 2026, an estimated $1.22K.
  • Cartesian Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1596 holding.
  • Essential Partners first reported a position in Cartesian Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.